BioCryst Pharmaceuticals, Inc.
(NASDAQ : BCRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.33%201.481.2%$403.44m
GILDGilead Sciences, Inc.
-0.58%72.360.9%$392.19m
CELGCelgene Corporation
0.47%87.611.2%$340.73m
BIIBBiogen Inc.
0.22%335.151.2%$274.58m
ILMNIllumina, Inc.
0.48%348.903.5%$253.46m
REGNRegeneron Pharmaceuticals, Inc.
-1.41%381.032.6%$207.27m
EXASExact Sciences Corporation
-1.58%72.1825.3%$195.57m
VRTXVertex Pharmaceuticals Incorporated
0.33%176.381.9%$160.40m
SRPTSarepta Therapeutics, Inc.
-0.36%151.8016.4%$124.42m
AAgilent Technologies, Inc.
-0.53%68.711.5%$120.84m
ALXNAlexion Pharmaceuticals, Inc.
0.82%118.782.0%$108.38m
ALNYAlnylam Pharmaceuticals, Inc
-0.08%93.289.7%$95.74m
NKTRNektar Therapeutics
-1.08%57.685.6%$94.93m
BMRNBioMarin Pharmaceutical Inc.
-0.07%98.084.4%$90.62m
INCYIncyte Corporation
0.22%67.172.5%$87.90m

Company Profile

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.